Huiling Luo1, Hongmei Han1, Xiaoli Liu1, Qin Liu2. 1. The Second People's Hospital of Lanzhou City, Lanzhou 730046, Gansu Province, China. 2. Fuling Central Hospital of ChongQing City, Chongqing 408000, China.
Abstract
BACKGROUND: Bronchial asthma (BA) is a chronic airway inflammatory disease with reversible airflow limitation as the main clinical manifestations, such as wheezing, cough, shortness of breath, chest tightness, etc, mediated by a variety of inflammatory cells, which can be recurrent. Clinical can improve symptoms, but cannot be cured; glucocorticoid is the most important first-line medication. Clinical practice has shown that montelukast sodium combined with fluticasone in the treatment of adult BA can improve clinical efficacy and reduce adverse reactions. The purpose of this study is to systematically study the efficacy and safety of montelukast sodium combined with fluticasone in the treatment of adult BA. METHODS: The Chinese databases (CNKI, VIP, Wanfang, Chinese Biomedical Database) and English databases (PubMed, the Cochrane Library, Embase, Web of Science) were searched by computer, for the randomized controlled clinical studies of montelukast sodium combined with fluticasone in the treatment of adult BA from establishment of database to October 2020. Two researchers independently extracted the relevant data and evaluated the quality of the literatures, and used RevMan5.3 software to conduct meta-analyze of the included literatures. RESULTS: This study assessed the efficacy and safety of montelukast sodium combined with fluticasone in the treatment of adult BA through total effective rate, pulmonary function (FEV1, FVC, PEF, FEV1/FVC), and adverse reactions. CONCLUSION: This study will provide reliable evidence-based evidence for the clinical application of montelukast sodium combined with fluticasone in the treatment of adult BA. OSF REGISTRATION NUMBER: DOI 10.17605/OSF.IO/CKQFM.
BACKGROUND: Bronchial asthma (BA) is a chronic airway inflammatory disease with reversible airflow limitation as the main clinical manifestations, such as wheezing, cough, shortness of breath, chest tightness, etc, mediated by a variety of inflammatory cells, which can be recurrent. Clinical can improve symptoms, but cannot be cured; glucocorticoid is the most important first-line medication. Clinical practice has shown that montelukast sodium combined with fluticasone in the treatment of adult BA can improve clinical efficacy and reduce adverse reactions. The purpose of this study is to systematically study the efficacy and safety of montelukast sodium combined with fluticasone in the treatment of adult BA. METHODS: The Chinese databases (CNKI, VIP, Wanfang, Chinese Biomedical Database) and English databases (PubMed, the Cochrane Library, Embase, Web of Science) were searched by computer, for the randomized controlled clinical studies of montelukast sodium combined with fluticasone in the treatment of adult BA from establishment of database to October 2020. Two researchers independently extracted the relevant data and evaluated the quality of the literatures, and used RevMan5.3 software to conduct meta-analyze of the included literatures. RESULTS: This study assessed the efficacy and safety of montelukast sodium combined with fluticasone in the treatment of adult BA through total effective rate, pulmonary function (FEV1, FVC, PEF, FEV1/FVC), and adverse reactions. CONCLUSION: This study will provide reliable evidence-based evidence for the clinical application of montelukast sodium combined with fluticasone in the treatment of adult BA. OSF REGISTRATION NUMBER: DOI 10.17605/OSF.IO/CKQFM.
Authors: Susan Langer; Johannes Horn; Alexander Kluttig; Rafael Mikolajczyk; Stefan Karrasch; Holger Schulz; Heinz-Erich Wichmann; Jakob Linseisen; Lina Jaeschke; Tobias Pischon; Julia Fricke; Thomas Keil; Wolfgang Ahrens; Kathrin Günther; Oliver Kuß; Tamara Schikowski; Börge Schmidt; Karl-Heinz Jöckel; Karin B Michels; Claus-Werner Franzke; Heiko Becher; Annika Jagodzinski; Stefanie Castell; Yvonne Kemmling; Wolfgang Lieb; Sabina Waniek; Kerstin Wirkner; Markus Löffler; Rudolf Kaaks; Karin Halina Greiser; Klaus Berger; Nicole Legath; Claudia Meinke-Franze; Sabine Schipf; Michael Leitzmann; Hansjörg Baurecht; Korbinian Weigl; Efrat Amitay; Cornelia Gottschick Journal: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz Date: 2020-04 Impact factor: 1.513